PARIS -- Boston Scientific Corporation (NYSE: BSX) announced European commercial availability of its new cardiac rhythm management connector system. The ENDOTAK RELIANCE 4-SITE lead system consists of the company's ENDOTAK RELIANCE 4-SITE defibrillation lead and compatible COGNIS cardiac resynchronization therapy defibrillators (CRT-Ds) and TELIGEN implantable cardioverter defibrillators (ICDs).
The system is designed to simplify the implant procedure by combining three terminals into one integrated connector, further reducing the volume of the company's small and thin high-energy CRT-Ds and ICDs. The company announced CE Mark and first implant of this system in May 2009.
RELATED NEWS: Bal Seal to demo implantable cardiac electrical contact
"Boston Scientific commissioned a prospective, multi-center observational clinical study involving more than 400 patients to extensively evaluate the 4-SITE system and to demonstrate appropriate clinical performance before making it broadly available in Europe," said Poul Erik Bloch Thomsen, M.D., Ph.D., Gentofte University Hospital, Copenhagen, Denmark. "The study examined both shocking and pacing performances and showed that the 4-SITE system increased the simplicity and overall efficiency of the implant procedure, and further reduced the already low likelihood of complications arising from connections being reversed."
RELATED NEWS: Hypertronics intros bio-compatible high rel contacts for implantable medical electronics
"The launch of the ENDOTAK RELIANCE 4-SITE lead system is another significant milestone for our Company, which spans from the first human implant of the ICD 30 years ago to manufacturing the smallest, thinnest high energy devices today," said Fred Hrkac, President of Europe, Middle East and Africa (EMEA) for Boston Scientific. "This system represents the next advance for the ENDOTAK RELIANCE lead family, which has demonstrated reliability in more than 400,000 implants worldwide."
For more information, visit: http://www.bostonscientific.com.
